Navigation Links
Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
Date:12/5/2013

AUSTIN, Texas, Dec. 5, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM and Yuri Pikover to its Board of Directors.

Dr. McCracken has more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head of Business Development & Licensing at Roche Pharmaceuticals where he was responsible for Roche's global in-licensing and out-licensing activities. Prior to joining Roche, Dr. McCracken held the position of Vice President of Business Development at Genentech for more than a decade.

Mr. Pikover is a Managing Director of 37 Technology Ventures, a boutique venture fund focusing on growing startups, and currently serves on the boards of numerous companies. From 1993 to 2008, he founded and held executive roles at Xylan, Access360, 5square and Folsom Lake Nissan, and served on the boards of several dozen companies. Prior to 1993, Yuri held technical and management positions with Micom Systems and Fibermux Corporation.

"We are delighted to welcome Joseph and Yuri to our Board of Directors at an exciting time for the company," said Rob Neville, CEO, Savara Pharmaceuticals. "The two bring a breadth of business development and public company experience to our team that will help achieve our long term growth objectives."

Last April, Savara Pharmaceuticals announced the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. AeroVanc is the first inhaled antibiotic being developed to address the growing population of MRSA lung-infected CF patients.

About AeroVanc
Vancomycin is an FDA-approved intravenously administered antibiotic with proven efficacy in the treatment of MRSA infections. AeroVanc is an investigational, proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in CF patients. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is thereby expected to reduce the risk of systemic drug-related side effects.

About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company developing AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. For more information, please see Savara's website at www.savarapharma.com, or www.aerovanc.com, or find us on Twitter, Facebook and LinkedIn.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
2. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
3. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
4. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
5. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 2017 , ... A minimally invasive porcelain veneer is increasing ... Association of Dental Laboratories (NADL) is informing dentists about the benefits of minimally ... dental laboratories and technicians that create these veneers. , According to National ...
(Date:3/28/2017)... Kennett Square, PA (PRWEB) , ... March 28, 2017 , ... ... reputation online and across a variety of business channels. , While many results ... aspects of any public relations program. , When it comes to measurement, firms ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):